143 results about "Antibody activity" patented technology

The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

The invention discloses a FUT8 gene knockout method based on a CRISPR technology. The FUT8 gene knockout method comprises: 1) designing a sgRNA sequence; 2) recombining the sgRNA sequence into a first vector to obtain a second vector; 3) transfecting the second vector into cells, and extracting DNA; 4) carrying out PCR amplification; 5) carrying out denaturation and annealing on the PCR product to form a heterologous hybrid double-stranded DNA; 6) cutting the heterologous hybrid double-stranded DNA, and analyzing the product to obtain the NHEJ occurring proportion in each cell population; and 7) selecting the cell population having the high NHEJ occurring proportion, carrying out limiting dilution method cloning, screening the monoclonal cell, and carrying out expanded culture to obtain the FUT8 gene knockout antibody. The invention further discloses the sgRNA sequence for the method. According to the present invention, the sgRNA capable of recognizing the FUT8 gene specific sequence is encoded, and the sgRNA and the sequence encoding the endonuclease are transfected into the cells, such that the FUT8 gene inactivation purpose is achieved, and the activity of the antibody ADCC is improved.

An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-Osp borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of OspC.

The present invention provides an antihuman TNF-α antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-α antibody; and a kit preparation wherein a freeze-dried antihuman TNF-α antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-α antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.

The invention relates to a preparation method of cystatin C antibody and a preparation method of a detection kit. Cystatin C (Cys C) is currently one of the most sensitive diagnostic markers for clinical kidney disease. The antibody preparation of the present invention is extracted and purified from human normal serum, and then a highly sensitive antigen is obtained by artificial modification. Animals were immunized multiple times to obtain hyperimmune serum containing Cys C antibody, and high-purity Cys C antibody was obtained by affinity chromatography. During the preparation process, the loss of antibody activity is small, and it is easy to produce in batches, and the antibody has high affinity and high titer, and does not generate cross-immune reaction. After the antibody is coupled with polystyrene latex balls, the prepared detection kit has higher sensitivity and linear range, good repeatability, low detection limit, easy automatic analysis, fast and simple operation. Due to the high purity of the antibody, the content of heteroantibody is very small, so there is less interference and the matrix is ​​stable.

The invention discloses a preparation method and application of D-dimer immuno latex microspheres. In the preparation method of D-dimer immuno latex microspheres, a chemical crosslinking method is optimized, the carboxyl of polystyrene microsphere is activated in a low-pH condition and then coupled with amino of an antibody dissolved in a high-pH condition, and the mixture of the two is neutral and is coupled for 12-24h at a low temperature, so that not only can the coupling efficiency of the antibody be guaranteed, but also the damage of the antibody activity caused by an activator is reduced to a great extent. A latex enhanced turbidimetric immunoassay D-dimer test kit prepared from the immuno latex microspheres prepared by the method has the characteristics of high sensitivity, accurate quantification, good repeatability and stable property, and the lowest detection limit can reach 0.01mg/L; the latex enhanced turbidimetric immunoassay D-dimer test kit can be applied to a full-automatic biochemical analyzer or coagulation analyzer, is quick and easy to operate, only needs 5-10 minutes from detection to result collection and has relatively good clinical application prospect.

The invention relates to a novel method of preparing agarose magnetic microspheres and application of the prepared agarose magnetic microspheres to separation and purification of an IgG antibody by utilization of an immunomagnetic separation technique. In specific, active amino is introduced to surfaces of the agarose magnetic microspheres, glutaraldehyde is adopted as a crosslinking arm to crosslink a ligand, and the ligand is staphylococcus aureus protein A capable of being specifically combined with the IgG antibody, thus preparing immunomagnetic microspheres capable of specifically adsorbing the IgG antibody. In addition, lysate of bacteria generating the IgG antibody by fermentation is separated and purified by utilization of a magnetic separation and purification device, the activity of the prepared antibody can reach 1.5*10<8> g IU/mg, the corresponding activity recovery rate is more than 90%, the purity of the antibody is almost 100% by purification analysis, and each index meets the national standards.

The invention discloses a preparation method for a single-chain antibody based on a hybridoma cell. The preparation method comprises the following steps: carrying out inverse transcription with total mRNA of the hybridoma cell as a template to obtain cDNA and selecting and using universal primers with low degeneracy for amplification of a complete set of heavy chain variable region and light chain variable region genes of the antibody; inputting sequences of the amplified heavy chain and light chain variable region genes into an IMGT database for analysis and eliminating antibody genes and nonsense genes originated from the hybridoma cell so as to obtain candidate heavy chain and light chain variable region genes; translating the genes into amino acid sequences, carrying out three dimensional structural homology modeling to obtain a three dimensional simulation structure of the single-chain antibody and carrying out molecular docking analysis on the three dimensional simulation structure and a corresponding antigen target molecule; and splicing a candidate heavy chain and a candidate light chain with correct analysis results into a single-chain antibody gene by using an overlap extension PCR method and carrying out expression and identification of antibody activity. The preparation method provided by the invention is applicable to preparation of all the single-chain antibodies originated from monoclonal hybridoma cells; the process of the preparation method is simple and rapid, and a prepared product has high quality.

The present invention provide a bispecific molecule comprising an antibody that binds a C3b-like receptor linked to one or more non-neutralizing antigen-binding antibodies or fragments thereof. The present invention also provides methods to identify non-neutralizing antibodies, and particularly, to identify enhancing antibodies. Methods of producing such bispecific molecules and their therapeutic and/or prophylactic uses are also provided by the present invention

The invention provides a monoclonal antibody for detecting porcine C-reactive protein (CRP), and preparation and application thereof. A gene engineering process is performed to obtain high-purity CRP recombinant protein; and the recombinant protein is utilized to screen out the hybridoma cell strain with the highest stability and highest antibody activity for secreting CRP protein antibody, wherein the collection number is CGMCC NO.9345. The monoclonal antibody generated by the hybridoma cell strain has the advantages of high specificity, high affinity and simple and efficient preparation method, and can monitor the CRP content in porcine serum, perform differential diagnosis on bacterial and virus diseases and perform auxiliary observation on treatment effects, thereby promoting the rational use of antibiotics, reducing the drug residues and ensuring the safety of animal food.

The invention relates to a method for preparing a yolk immunoglobulin vaccine for resisting porphyromonas gingivalis, which comprises the following operating steps of: (1) culturing and separating an international standard strain of the porphyromonas gingivalis to obtain the porphyromonas gingivalis; (2) obtaining mycoprotein of the porphyromonas gingivalis; (3) mixing a whole bacterium soluble protein antigen of the porphyromonas gingivalis with a freunds incomplete adjuvant uniformly to prepare an intravenous injection preparation, performing an intravenous injection under a chicken wing of a laying hen, and collecting eggs laid by the laying hen; and (4) extracting yolk immunoglobulin for resisting the porphyromonas gingivalis in the eggs. The method has a low production cost and a high yield because 100 milligrams of the yolk immunoglobulin can be obtained from one egg; and the method is simple, convenient and quick to operate and has the advantages of heat resistance, acid resistance, good stability and the like. Under an acid condition of which the temperature is not over 75 DEG C and the pH is more than 4, the yolk immunoglobulin vaccine can still well maintain the biological activity, can be stored for about 3 months at the normal temperature, and can be stored for 6 to 12 months at 4 DEG C with non-decreased antibody activity.

The invention discloses a single-chain antibody ScFv for resisting influenza viruses, a preparation method for the single-chain antibody ScFv, application of the single-chain antibody ScFv, a gene for encoding the single-chain antibody ScFv, a carrier containing the gene, a host cell and the like. The single-chain antibody ScFv for resisting the influenza viruses is one of the following proteins: 1) a single-chain antibody formed by connecting a heavy chain variable region and a light chain variable region of the antibody through a linker peptide, wherein an amino acid sequence of the light chain variable region and an amino acid sequence of the heavy chain variable region are shown as SEQ ID NO.1 and SEQ ID NO.2 in a sequence table respectively; and 2) a derived antibody obtained by improving the single-chain antibody in step 1), wherein the improvement comprises the deletion, substitution or insertion of amino acid, and the derived antibody has the antibody activity of resisting H1N1 influenza viruses. The molecular weight of the single-chain antibody is about 27kD; and the single-chain antibody can specifically identify the H1N1 influenza viruses and block the combination of the viruses and natural serum. The single-chain antibody can be used for diagnosing, preventing, controlling and treating the infection of the H1N1 influenza viruses, or is used for antiviral breeding of transgenic animals.

The present invention relates to a chicken vitellus antibody (anti-HPTxIgY) with antibody activity for resisting pyloric helicobacterium cytotoxin, its preparation method and application in the preparation of medicine and health-care product for curing related diseases resulted from pyloric helicobacterium infection and preparation for detecting these related diseases. The above-mentioned antibody is undergone the process of IgY purity checking treatment. PAGE electrophoressi can be used for detecting purified vitallus antibody purity. Only one electrophoretic band is produced in the electrophoresis, and an UV spectrophotometer is used for determination so as to calculate the albumen concentration (mg/ml) which is (1.45XOD 280nm-0.74XOD 260nm)X dilute multiple. The above-mentioned method is as follows: preparing pyloric helicobacterium cytotoxin antigen, immunizing health hen with said antigen, collecting egg and extracting anti-HPTxIgY from the egg.

The invention discloses a fusion protein based on anti-EGFR single-chain antibody and arginine nonamer, and applications of the fusion protein. The fusion protein comprises a heavy chain variable region and a light chain variable region which are connected via connection peptides; the terminal of the light chain variable region is connected with the arginine nonamer; and amino acid sequence of the arginine nonamer is represented by SEQ ID No.3. According to the fusion protein, the heavy chain variable region and the light chain variable region of the anti-EGFR single-chain antibody are connected via the selected connection peptides, so that specificity and affinity of combination of the antibody with EGFR are maintained, and targeting performance of the constructed fusion protein on EGFR is ensured; the size of the fusion protein is reduced, so that on the one hand construction, expression and purification of the fusion protein are convenient, and cost is reduced, and on the other hand, combination of the fusion protein on EGFR is ensured, demands on molecular size and antibody activity during cellular internalization are ensured, and feasibility and accuracy of the combination of the fusion protein on EGFR and targeting tumor cellular internalization are ensured.

A method for fixing antibody on the surface of medical instrument, mainly includes: 1) pre-treating the instrument surface; 2) preparing holes: preparing multicrystal phase structure which has same size holes in the surface of the instrument by chemical corrosion, electrochemical corrosion, anodic oxidation, micro-arc oxidation, micro-arc nitridation; 3) post-treating the instrument surface; 4) fixing the antibody: immerging the bare metal scaffold which has holes in surface into a buffer solution containing antibody, adjusting the pH value of the antibody buffer solution, fixing the antibody on the surface of the instrument by the attraction between positive and negative charge and hole effect; and 5) confirming the effectiveness of the fixed antibody by artificial simulation hemodynamics and detecting method of antibody activity in scaffold surface. The method can promote the firm degree of the antibody which is fixed on the surface of the instrument, and keep high activity of the antibody on the surface of medical instrument.

A genetic engineering antibody combined with a specificity of B lymphocyte stimulator (Blys), a pharmaceutical composition containing the antibody, and a kit. A heavy chain variable region of the genetic engineering antibody contains amino acid sequences shown by SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3, or a light chain variable region of the genetic engineering antibody contains amino acid sequences shown by SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6. The present invention further provides an anti-Blys monoclonal antibody, generated by a cell line with a preservation number being CGMCC No.7352.

The invention discloses a nucleic acid detection method and a kit. According to a to-be-detected target nucleic acid sequence, three molecular probes A, B and C with stem-loop structures are designed. When a sample contains the target nucleic acid sequence, an a* area of a target nucleic acid and an a area of the probe A are bound, a fulcrum mediated strand displacement reaction is triggered, the stem-loop structures of the probes B and C are sequentially opened and boundwith the mixture, and finally a large number of Y-type nucleic acid nanostructures are generated. The Y-type nucleic acid nanostructures have antibody activity, and results can be observed with naked eyes through a corresponding binding reaction and a chromogenic reaction. The fulcrum mediated strand displacement signal amplification strategy does not need protease and the thermal denaturating annealing process. The method is high in sensitivity, the detection limit of nucleic acids is 5 fM, specificity is good, the nucleic acids with single base mutation can be recognized, and the method is easy and quick to use and can be used for detecting 96 or 384 samples at the same time.